Adeno-associated viral vectors (AAV) have emerged as key players in this growth trajectory, projected to capture a ...

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant ...

If the influenza virus infecting cattle workers starts a pandemic, help in the form of a vaccine is months away ...

VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why ...

ProBioGen’s AGE1.CR.PIX been developed as a stable proliferating avian cell line that is highly permissive for different ...

The partnership between Transgene and ProBioGen underscores a shared commitment to advancing the field of individualized medicine and to support manufacturing scalability and optimization.

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Key milestone reached within expected initial timelines with successful set up of cell growth and production of HIV-1 vaccine candidate at bench scal ...

Transgene, ProBioGen join forces to advance individualized cancer vaccine development: Strasbourg, France Thursday, November 7, 2024, 11:00 Hrs [IST] Transgene, a biotech company ...

myvac is a viral vector (MVA—Modified Vaccinia Ankara ... This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC’s Neoantigen Prediction ...